Drug intelligence / Profile preview

azithromycin + cefixime

Development stage
Phase 4
Lead developer
PLIVA
Modality
Small Molecules
Administration
Oral
01

Overview

Azithromycin + cefixime is a fixed-dose combination of two antibiotics used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, sexually transmitted infections (such as gonorrhea), skin and soft tissue infections, ear and throat infections, and typhoid fever. Cefixime is a third-generation cephalosporin antibiotic that works by inhibiting the synthesis of the bacterial cell wall, leading to cell lysis and death. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination provides broad-spectrum antibacterial coverage against both intracellular (azithromycin) and extracellular (cefixime) pathogens[1][5][7]. This dual mechanism may help limit resistance development in certain settings such as typhoid fever[2][7].

Brand names
Zifi-AZTaxim-AZOmnicef AZHifen-AZBrutacef AZZithrox PlusCefolac-AZAzilin PlusRitolideAzinix Plus
Other names
cefixime + azithromycin
02

Targets

Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on azithromycin + cefixime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + cefixime.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call